CJC-1295 + Ipamorelin

Research Use Only

All products are intended solely for laboratory research and are not for human or animal consumption. By purchasing, the buyer agrees to use these products in compliance with all applicable laws.

CJC-1295 + Ipamorelin Overview

The CJC-1295 + Ipamorelin blend combines two peptides studied for their effects on endocrine signaling pathways. CJC-1295, a GHRH analog, is associated with sustained modulation of somatotroph axis activity and downstream signaling cascades. Ipamorelin, a selective secretagogue-type peptide, has been studied for its selective pituitary signaling activity without significant off-target pathway interference. Together, they may provide complementary activity across multiple endocrine and systemic pathways in experimental settings.

Teichman S.L. et al. (2006).

History

The concept of the CJC-1295 + Ipamorelin blend stems from parallel developments in peptide research aimed at exploring growth hormone modulation. CJC-1295, a synthetic analog of growth hormone–releasing hormone (GHRH), was developed in the early 2000s to extend the half-life and activity of natural GHRH fragments for research into growth hormone and IGF-1 pathways. Meanwhile, Ipamorelin—a selective ghrelin receptor agonist—emerged from studies in the 1990s investigating ghrelin mimetics and their ability to stimulate growth hormone release with minimal off-target hormonal effects. Together, these peptides became of interest for laboratory research into growth hormone regulation, recovery, and metabolic processes.Svensson J. et al. (1998).

CJC-1295 Structure

Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂Molecular Weight: 3367.9 g/mol

PubChem ID: 91976842

Research Findings

CJC-1295 and Ipamorelin have been examined in endocrine, signaling, experimental, and systemic models, with research exploring their influence on somatotroph axis pathways, downstream cascades, pathway activity, and molecular viability. Studies highlight their role in signaling kinetics, remodeling processes, and systemic resilience in preclinical settings.Key Areas of Research:

• Endocrine: Somatotroph axis, signaling, cascades
• Signaling: Lipid pathways, dynamics, markers
• Molecular: Proliferation, remodeling, viability
• Systemic: Vascular, resilience, pathway activity

Together, these findings suggest broad experimental potential for CJC-1295 and Ipamorelin across multiple biological pathways. By modulating endocrine signaling, influencing downstream pathway activity, and supporting molecular and systemic resilience, this combination provides a versatile platform for research into remodeling, pathway dynamics, and experimental modeling in laboratory settings.Teichman S.L. et al., Journal of Clinical Endocrinology & Metabolism, 2006

References

Teichman S.L. et al. (2006). Prolonged stimulation of GH and IGF-1 secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab, 91(3):799-805. Lapierre S.S. et al. (2006). Sustained GH and IGF-1 responses to CJC-1295 in GHRH knockout mice. Am J Physiol Endocrinol Metab, 291(2):E282-E287.Svensson J. et al. (1998). Ipamorelin selectively stimulates GH release without affecting cortisol or prolactin. J Clin Endocrinol Metab, 83(9):3094-3101.Culler M.D. et al. (2002). Pharmacological characterization of ipamorelin, a novel GHRP with GH selectivity. J Endocrinol, 174(2):R1-R6.